QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:BTTX

Better Therapeutics (BTTX) Stock Price, News & Analysis

$0.01
+0.00 (+8.53%)
(As of 04:28 PM ET)
Today's Range
$0.0127
$0.0160
50-Day Range
$0.01
$0.22
52-Week Range
$0.01
$1.61
Volume
898,475 shs
Average Volume
6.79 million shs
Market Capitalization
$698,040.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Better Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
42,453.2% Upside
$6.00 Price Target
Short Interest
Bearish
8.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of Better Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.86) to ($0.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.03 out of 5 stars

BTTX stock logo

About Better Therapeutics Stock (NASDAQ:BTTX)

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

BTTX Stock Price History

BTTX Stock News Headlines

Better Therapeutics (BTTX) Set to Announce Earnings on Thursday
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Dow Dips Over 100 Points; Dick's Sporting Goods Earnings Top Views
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
CAH Feb 2024 107.000 put
Biora Therapeutics Provides Outlook for 2024
See More Headlines
Receive BTTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Better Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Health services
Sub-Industry
N/A
Current Symbol
NASDAQ:BTTX
Fax
N/A
Employees
54
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$9.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+46,053.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-39,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.04) per share

Miscellaneous

Free Float
24,233,000
Market Cap
$648,180.00
Optionable
Optionable
Beta
2.35
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. David P. Perry M.B.A. (Age 56)
    Co-Founder & Executive Chairman
    Comp: $260k
  • Mr. Frank L. Karbe (Age 56)
    CEO, Interim CFO, President & Director
    Comp: $533.37k
  • Dr. Mark A. Berman M.D. (Age 49)
    Chief Medical Officer
    Comp: $573.75k
  • Ms. Kristin Wynholds (Age 52)
    Chief Product Officer
    Comp: $519.07k
  • Mr. Andres Camacho
    Senior VP of Technology & Head of Engineering
  • Ms. Angela Willis
    Senior Vice President of Market Access
  • Ms. Jessica Meng
    Chief Commercial Officer
  • Leslie Miller
    Controller

BTTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Better Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Better Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BTTX shares.
View BTTX analyst ratings
or view top-rated stocks.

What is Better Therapeutics' stock price target for 2024?

3 brokerages have issued 1-year price objectives for Better Therapeutics' shares. Their BTTX share price targets range from $3.00 to $9.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 42,453.2% from the stock's current price.
View analysts price targets for BTTX
or view top-rated stocks among Wall Street analysts.

How have BTTX shares performed in 2024?

Better Therapeutics' stock was trading at $0.1950 at the beginning of the year. Since then, BTTX stock has decreased by 92.8% and is now trading at $0.0141.
View the best growth stocks for 2024 here
.

Are investors shorting Better Therapeutics?

Better Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 2,560,000 shares, an increase of 20.2% from the February 29th total of 2,130,000 shares. Based on an average daily trading volume, of 6,410,000 shares, the days-to-cover ratio is presently 0.4 days. Approximately 8.3% of the company's stock are short sold.
View Better Therapeutics' Short Interest
.

When is Better Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our BTTX earnings forecast
.

Who are Better Therapeutics' major shareholders?

Better Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include MMCAP International Inc. SPC (0.71%), Vanguard Group Inc. (0.40%), Vanguard Group Inc. (0.40%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Andrew J Armanino, David P Perry, Elder Granger, Frank Karbe, Geoffrey M Parker, Kevin J Appelbaum, Mark A Berman, Mark Heinen and Risa J Lavizzo-Mourey.
View institutional ownership trends
.

How do I buy shares of Better Therapeutics?

Shares of BTTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BTTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners